sickle cell disease

(iStock image)
March 14, 2025

Blood formation and disorders expert Stuart Orkin to present Discovery Lecture March 27

Orkin’s research led to a gene therapy for sickle cell disease and beta-thalassemia; it is the first Food and Drug Administration-approved CRISPR-based gene therapy.

By Leigh MacMillan
(iStock)
February 27, 2025

VUMC part of new study validating curative therapy for sickle cell disease

Of 38 adults with severe SCD who participated in the study, more than 97% no longer required immunosuppressive therapy one year after the transplant.

By Bill Snyder
June 25, 2024

International trial introduces another curative option for sickle cell disease 

The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.

By Jessica Pasley
(iStock image)
April 24, 2024

VUMC hosts symposium on stem cell transplants and cellular therapies

The Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium offers clinicians detailed information on the latest developments for hematological diseases, ranging from immunotherapies for blood cancers to new, curative therapies for sickle cell disease.

By Tom Wilemon
Michael DeBaun, MD, MS, MPH
March 24, 2022

VUMC’s DeBaun elected president-elect of the American Pediatric Society

Vanderbilt’s Michael DeBaun, MD, MS, MPH, has been elected president-elect of the American Pediatric Society.

By Nancy Humphrey
October 7, 2021

No detail is too small and no task too big for research administrative officer Mustafa Nateqi

Nateqi’s can-do attitude and dedication earn him a Credo Award.

By Christina Echegaray
July 29, 2019

DeBaun’s mentoring honored by American Society of Hematology

Michael DeBaun, MD, MPH, has been awarded the American Society of Hematology’s 2019 ASH Mentor Award for his sustained and outstanding commitment to the training and career development of early career hematologists.
By Christina Echegaray
February 22, 2017

Risk of death in sickle cell disease

Two factors commonly used to evaluate patients with sickle cell disease are associated with each other and can predict increased mortality, Vanderbilt researchers have discovered.
By Meredith Jackson
September 22, 2016

Effort set to help sickle cell patients manage meds

Vanderbilt University Medical Center is part of a 6-year, $4.4 million grant from the National Institutes of Health to improve the use of prescribed medication by sickle cell patients.
By VUMC News and Communications
October 9, 2014

Vanderbilt’s DeBaun to deliver annual Levi Watkins Jr. Lecture

Michael R. DeBaun, M.D., J.C. Peterson Professor of Pediatrics and Medicine at Vanderbilt, will be the keynote speaker at the 13th Annual Levi Watkins Jr. Lecture.
By Jessica Pasley
August 21, 2014

Transfusions ease strokes for children with sickle cell

Vanderbilt-led research found regular blood transfusion therapy significantly reduces the recurrence of strokes in children with sickle cell anemia who have previously had "silent" strokes.
By Christina Echegaray
August 15, 2014

Levi Watkins Jr. Lecture to feature DeBaun

The Levi Watkins Jr. Lecture will be held Oct. 14, featuring keynote speaker Michael R. DeBaun.
By VUMC News and Communications
August 14, 2014

DeBaun’s sickle cell disease research honored

Michael R. DeBaun, M.D., MPH, has been recognized by the American Society of Hematology (ASH) for his significant contributions and research advances in the area of sickle cell disease.
By Christina Echegaray
1 2